SCHEMBL2908342

SCHEMBL2908342

OC1CCN(C(c2ccc(-c3ccc4c(c3)OCCO4)cc2)c2c[nH]nc2-c2ccco2)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB2 P05107 3/20 0.38
ICAM1 P05362 3/20 0.38
ITGAL P20701 3/20 0.38
SIRT1 Q96EB6 1/20 0.35
MAPT P10636 5/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
KDM4E B2RXH2 3/20 0.34
ALDH1A1 P00352 3/20 0.34
POLB P06746 2/20 0.34
HPGD P15428 2/20 0.34
ALOX15 P16050 2/20 0.34
HSD17B10 Q99714 2/20 0.34
USP2 O75604 1/20 0.34
THRB P10828 1/20 0.34
ALOX12 P18054 1/20 0.34
APEX1 P27695 1/20 0.34
MAPK1 P28482 1/20 0.34
CASP1 P29466 1/20 0.34
BRCA1 P38398 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2905003 0.87 SIRT1 (0.38) SIRT1MAPTMEN1KMT2AKDM4E
SCHEMBL2907737 0.87 LMNA (0.33) MAPTALDH1A1POLBTSHRKDM4D
SCHEMBL2908848 0.86 LRRK2 (0.36) MAPTMCL1KDM4D
SCHEMBL2904802 0.86 P4HB (0.38) SIRT1MAPTMEN1KMT2AKDM4E
SCHEMBL2901677 0.85 MAPT (0.39) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL2901687 0.85 TSHR (0.38) SIRT1MAPTMEN1KMT2AKDM4E
SCHEMBL2907788 0.85 LMNA (0.37) MAPTKDM4EALDH1A1HPGDHSD17B10
SCHEMBL2907051 0.84 ALDH1A1 (0.41) SIRT1MAPTMEN1KMT2AKDM4E
SCHEMBL5227650 0.83 SIRT1 (0.35) ITGB2ICAM1ITGALSIRT1MEN1
SCHEMBL2909115 0.82 PTK2 (0.36) SIRT1MAPTMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP claimed
US-7566709-B2 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2009-07-28 US disclosed
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders HTR1A, HTR1D, HTR5A ITGB2 4433/4885ICAM1 1936/4885ITGAL 3992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.